Browse CCL24

Summary
SymbolCCL24
Namechemokine (C-C motif) ligand 24
Aliases Ckb-6; MPIF-2; eotaxin-2; MPIF2; CK-beta-6; myeloid progenitor inhibitory factor 2; SCYA24; small inducible ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Chemotactic for resting T-lymphocytes, and eosinophils. Has lower chemotactic activity for neutrophils but none for monocytes and activated lymphocytes. Is a strong suppressor of colony formation by a multipotential hematopoietic progenitor cell line. Binds to CCR3.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0002548 monocyte chemotaxis
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0007015 actin filament organization
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0008360 regulation of cell shape
GO:0022604 regulation of cell morphogenesis
GO:0030041 actin filament polymerization
GO:0030335 positive regulation of cell migration
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030838 positive regulation of actin filament polymerization
GO:0031334 positive regulation of protein complex assembly
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0032271 regulation of protein polymerization
GO:0032273 positive regulation of protein polymerization
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0034341 response to interferon-gamma
GO:0034612 response to tumor necrosis factor
GO:0040017 positive regulation of locomotion
GO:0043254 regulation of protein complex assembly
GO:0043410 positive regulation of MAPK cascade
GO:0044089 positive regulation of cellular component biogenesis
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0048245 eosinophil chemotaxis
GO:0048247 lymphocyte chemotaxis
GO:0048514 blood vessel morphogenesis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050900 leukocyte migration
GO:0051258 protein polymerization
GO:0051272 positive regulation of cellular component movement
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0060326 cell chemotaxis
GO:0070098 chemokine-mediated signaling pathway
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070555 response to interleukin-1
GO:0071346 cellular response to interferon-gamma
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071621 granulocyte chemotaxis
GO:0071674 mononuclear cell migration
GO:0072676 lymphocyte migration
GO:0072677 eosinophil migration
GO:0090066 regulation of anatomical structure size
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1901342 regulation of vasculature development
GO:1904018 positive regulation of vasculature development
GO:1990266 neutrophil migration
GO:2000147 positive regulation of cell motility
GO:2000416 regulation of eosinophil migration
GO:2000418 positive regulation of eosinophil migration
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0008009 chemokine activity
GO:0042379 chemokine receptor binding
GO:0048020 CCR chemokine receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
Reactome -
Summary
SymbolCCL24
Namechemokine (C-C motif) ligand 24
Aliases Ckb-6; MPIF-2; eotaxin-2; MPIF2; CK-beta-6; myeloid progenitor inhibitory factor 2; SCYA24; small inducible ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCL24 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCCL24
Namechemokine (C-C motif) ligand 24
Aliases Ckb-6; MPIF-2; eotaxin-2; MPIF2; CK-beta-6; myeloid progenitor inhibitory factor 2; SCYA24; small inducible ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCL24 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.53 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCCL24
Namechemokine (C-C motif) ligand 24
Aliases Ckb-6; MPIF-2; eotaxin-2; MPIF2; CK-beta-6; myeloid progenitor inhibitory factor 2; SCYA24; small inducible ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCL24 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0830.785
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1220.816
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0560.899
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.5530.0923
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.520.301
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.5820.317
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3860.599
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7720.505
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1090.928
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5720.35
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.5720.502
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.9920.000633
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CCL24 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCCL24
Namechemokine (C-C motif) ligand 24
Aliases Ckb-6; MPIF-2; eotaxin-2; MPIF2; CK-beta-6; myeloid progenitor inhibitory factor 2; SCYA24; small inducible ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCL24. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCL24
Namechemokine (C-C motif) ligand 24
Aliases Ckb-6; MPIF-2; eotaxin-2; MPIF2; CK-beta-6; myeloid progenitor inhibitory factor 2; SCYA24; small inducible ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCL24. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCL24.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCL24
Namechemokine (C-C motif) ligand 24
Aliases Ckb-6; MPIF-2; eotaxin-2; MPIF2; CK-beta-6; myeloid progenitor inhibitory factor 2; SCYA24; small inducible ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCL24. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCL24
Namechemokine (C-C motif) ligand 24
Aliases Ckb-6; MPIF-2; eotaxin-2; MPIF2; CK-beta-6; myeloid progenitor inhibitory factor 2; SCYA24; small inducible ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCL24 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCL24
Namechemokine (C-C motif) ligand 24
Aliases Ckb-6; MPIF-2; eotaxin-2; MPIF2; CK-beta-6; myeloid progenitor inhibitory factor 2; SCYA24; small inducible ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCL24 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCL24
Namechemokine (C-C motif) ligand 24
Aliases Ckb-6; MPIF-2; eotaxin-2; MPIF2; CK-beta-6; myeloid progenitor inhibitory factor 2; SCYA24; small inducible ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCL24 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.